Clinical significance of t(11;14) translocation in systemic AL amyloidosis in the era of daratumumab therapy
Clinical and Experimental Medicine · 2025
DOI: 10.1007/s10238-025-02005-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Medicine, 2025. Verfasst von Nao Nishimura und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Rheumatology, and Infectious Diseases, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kuma…. Hauptthemen laut MEDLINE: Translocation, Genetic, Antibodies, Monoclonal, Immunoglobulin Light-chain Amyloidosis, Chromosomes, Human, Pair 14. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The chromosomal translocation t(11;14)(q13;q32) is frequently observed in systemic light-chain (AL) amyloidosis, yet its clinical significance in the era of daratumumab-based therapy remains unclear. To compare clinical and cytogenetic characteristics, we retrospectively analyzed 68 patients with systemic AL amyloidosis and 107 patients with multiple myeloma (MM) newly diagnosed at Kumamoto University Hospital, with the MM cohort serving as a reference cohort. t(11;14) was detected in 55.9% of AL amyloidosis and 28.0% of MM cases. In both diseases, t(11;14) was associated with light chain–only M-protein and elevated CD20 expression on bone marrow plasma cells, suggesting a distinct phenotype. Notably, t(11;14)-positive AL amyloidosis patients exhibited a significantly lower incidence of renal dysfunction, a feature not observed in t(11;14)-positive MM. Among 47 AL amyloidosis patients treated with upfront daratumumab-containing regimens, overall survival did not differ significantly by t(11;14) status. However, event-free survival was significantly shorter in the t(11;14)-positive group (median 41.6 vs. 71.3 months, p = 0.037), accompanied by inferior 3 months hematological and cardiac responses. These findings suggest that t(11;14)-positive AL amyloidosis constitutes a distinct biological and clinical subtype characterized by delayed treatment response to daratumumab. Tailored therapeutic strategies targeting the unique biology of t(11;14)-positive AL amyloidosis is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Rheumatology, and Infectious Diseases, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
- Department of Hematology, Rheumatology, and Infectious Diseases, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan. ykawanomn@kuh.kumamoto-u.ac.jp.
Zitieren
APA
Nishimura, N., Kawano, Y., & Yasunaga, J. I. (2025). Clinical significance of t(11;14) translocation in systemic AL amyloidosis in the era of daratumumab therapy. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-025-02005-2
Vancouver
Nishimura N, Kawano Y, Yasunaga JI. Clinical significance of t(11;14) translocation in systemic AL amyloidosis in the era of daratumumab therapy. Clinical and Experimental Medicine. 2025. doi:10.1007/s10238-025-02005-2
BibTeX
@article{Nishimura2025,
author = {Nishimura, Nao and Kawano, Yawara and Yasunaga, Jun-Ichirou},
title = {Clinical significance of t(11;14) translocation in systemic AL amyloidosis in the era of daratumumab therapy},
journal = {Clinical and Experimental Medicine},
year = {2025},
doi = {10.1007/s10238-025-02005-2}
}
EUVIMED